WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006091332) INTRANASAL ADMINISTRATION OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/091332    International Application No.:    PCT/US2006/003110
Publication Date: 31.08.2006 International Filing Date: 27.01.2006
IPC:
A61K 38/00 (2006.01), A61K 38/34 (2006.01), A61K 39/395 (2006.01), A61K 47/48 (2006.01), A61P 3/04 (2006.01)
Applicants: ALZA CORPORATION [US/US]; 1900 Charleston Road, Mountain View, California 94043 (US) (For All Designated States Except US).
BENTZ, Hanne [DE/US]; (US) (For US Only).
HILL, Beth [US/US]; (US) (For US Only).
LUCAS, Catherine [US/US]; (US) (For US Only).
FREY, William, H. [US/US]; (US) (For US Only)
Inventors: BENTZ, Hanne; (US).
HILL, Beth; (US).
LUCAS, Catherine; (US).
FREY, William, H.; (US)
Agent: MOHR, Judy, M.; Perkins Coie LLP, P.O. Box 2168, Menlo Park, California 94026 (US)
Priority Data:
60/655,809 23.02.2005 US
Title (EN) INTRANASAL ADMINISTRATION OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM
(FR) ADMINISTRATION INTRANASALE D'AGENTS ACTIFS DANS LE SYSTEME NERVEUX CENTRAL
Abstract: front page image
(EN)A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering the fusion polypeptide intranasally, for delivery to the central nervous system. Methods of treatment are also provided, where a therapeutically effective amount of the composition is delivered to the nasal cavity of a mammal.
(FR)Une méthode de largage d'un polypeptide dans le système nerveux central est décrite. Cette méthode consiste à fixer le polypeptide à un anticorps ou à un fragment d'anticorps et à administrer le polypeptide de fusion par voie intranasale, de manière qu'il soit largué dans le système nerveux central. Des méthodes de traitement dans lesquelles une dose efficace au plan thérapeutique de ladite composition est larguée dans la cavité nasale d'un mammifère, sont décrites.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)